p16 polyclonal antibody, anti-human, mouse
€0.00
In stock
SKU
BT-AP06744
Catalog Number: BT-AP06744
Size(s): 20μL, 50μL, 100μL
Isotype: Rabbit IgG
Reactivity: human, mouse
Application(s): WB, ELISA
Datasheet
Request Information
Size(s): 20μL, 50μL, 100μL
Isotype: Rabbit IgG
Reactivity: human, mouse
Application(s): WB, ELISA
Datasheet
Request Information
Background:
CDKN2A (cyclin dependent kinase inhibitor 2A) generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. CDKN2A is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Research Area: Others
Synonyms: CDKN2A, CDKN2, MTS1, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A
Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Concentration: 1 mg/ml
Storage:
-20°C for 1 year
CDKN2A (cyclin dependent kinase inhibitor 2A) generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. CDKN2A is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.
Research Area: Others
Synonyms: CDKN2A, CDKN2, MTS1, Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3, Cyclin-dependent kinase 4 inhibitor A, CDK4I, Multiple tumor suppressor 1, MTS-1, p16-INK4a, p16-INK4, p16INK4A
Immunogen: The antiserum was produced against synthesized peptide derived from human AMPK alpha around the phosphorylation site of Thr172. AA range:140-189
Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Formulation: Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Concentration: 1 mg/ml
Storage:
-20°C for 1 year
| Is Featured? | No |
|---|
Write Your Own Review